4XRY

Human Cytochrome P450 2D6 BACE1 Inhibitor 5 Complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.251 
  • R-Value Work: 0.208 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.

Brodney, M.A.Beck, E.M.Butler, C.R.Barreiro, G.Johnson, E.F.Riddell, D.Parris, K.Nolan, C.E.Fan, Y.Atchison, K.Gonzales, C.Robshaw, A.E.Doran, S.D.Bundesmann, M.W.Buzon, L.Dutra, J.Henegar, K.LaChapelle, E.Hou, X.Rogers, B.N.Pandit, J.Lira, R.Martinez-Alsina, L.Mikochik, P.Murray, J.C.Ogilvie, K.Price, L.Sakya, S.M.Yu, A.Zhang, Y.O'Neill, B.T.

(2015) J.Med.Chem. 58: 3223-3252

  • DOI: 10.1021/acs.jmedchem.5b00191
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer's disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Herein ...

    In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer's disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Herein, we describe the discovery of a novel class of potent, low clearance, CNS penetrant BACE1 inhibitors represented by thioamidine 5. Further profiling suggested that a high fraction of the metabolism (>95%) was due to CYP2D6, increasing the potential risk for victim-based drug-drug interactions (DDI) and variable exposure in the clinic due to the polymorphic nature of this enzyme. To guide future design, we solved crystal structures of CYP2D6 complexes with substrate 5 and its corresponding metabolic product pyrazole 6, which provided insight into the binding mode and movements between substrate/inhibitor complexes. Guided by the BACE1 and CYP2D6 crystal structures, we designed and synthesized analogues with reduced risk for DDI, central efficacy, and improved hERG therapeutic margins.


    Organizational Affiliation

    #The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92024, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cytochrome P450 2D6
A, B, C, D
479Homo sapiensMutation(s): 0 
Gene Names: CYP2D6 (CYP2DL1)
EC: 1.14.14.1
Find proteins for P10635 (Homo sapiens)
Go to Gene View: CYP2D6
Go to UniProtKB:  P10635
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SI5
Query on SI5

Download SDF File 
Download CCD File 
A, B, C, D
(4aR,6R,8aS)-8a-(2,4-difluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)-4,4a,5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-amine
C17 H18 F2 N4 O S
JYDYMWJEZLKIBS-CXMBCZLWSA-N
 Ligand Interaction
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B, C, D
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
HEM
Query on HEM

Download SDF File 
Download CCD File 
A, B, C, D
PROTOPORPHYRIN IX CONTAINING FE
HEME
C34 H32 Fe N4 O4
KABFMIBPWCXCRK-RGGAHWMASA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.251 
  • R-Value Work: 0.208 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 57.064α = 90.00
b = 192.341β = 90.00
c = 247.304γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
PHENIXphasing
Aimlessdata scaling
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2015-01-21 
  • Released Date: 2015-05-20 
  • Deposition Author(s): Johnson, E.F., Fan, Y.

Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesR01GM031001

Revision History 

  • Version 1.0: 2015-05-20
    Type: Initial release
  • Version 1.1: 2017-09-27
    Type: Author supporting evidence, Database references, Derived calculations, Source and taxonomy, Structure summary